Kanada - angličtina - Health Canada

janssen inc - darunavir (darunavir ethanolate) - tablet - 150mg - darunavir (darunavir ethanolate) 150mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 150mg - darunavir (darunavir ethanolate) 150mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 75mg - darunavir (darunavir ethanolate) 75mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 400mg - darunavir (darunavir ethanolate) 400mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 600mg - darunavir (darunavir ethanolate) 600mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 800mg - darunavir (darunavir ethanolate) 800mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

janssen inc - darunavir (darunavir ethanolate) - suspension - 100mg - darunavir (darunavir ethanolate) 100mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

janssen inc - darunavir (darunavir ethanolate); cobicistat - tablet - 800mg; 150mg - darunavir (darunavir ethanolate) 800mg; cobicistat 150mg - hiv protease inhibitors

Kanada - angličtina - Health Canada

abbvie corporation - ombitasvir; paritaprevir; ritonavir - tablet - 12.5mg; 75mg; 50mg - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg - hcv protease inhibitors

Spojené státy - angličtina - NLM (National Library of Medicine)

state of florida doh central pharmacy - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg - viramune is indicated for use in combination with other antiretroviral agents for the treatment of hiv-1 infection. this indication is based on one principal clinical trial (bi 1090) that demonstrated prolonged suppression of hiv-1 rna and two smaller supportive studies, one of which (bi 1046) is described below. additional important information regarding the use of viramune for the treatment of hiv-1 infection: - based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, viramune should not be initiated in adult females with cd4+ cell counts greater than 250 cells/mm3 or in adult males with cd4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see boxed warning and warnings and precautions (5.1) ]. - the 14-day lead-in period with viramune 200 mg daily dosing has been demonstrated to reduce the frequency of rash [see dosage and administration (2.4) and warnings and precautions (5.2) ]. - if rash persists beyond the 14-d